Pfizer agreed to share with HHS part of extra net revenue from higher overseas prices on existing drugs under its MFN deal. The provision runs Jan. 1, 2026–Jan. 20, 2029; the share and covered drugs are redacted. HHS says the money is intended to lower U.S. costs.
The provision is part of Pfizer’s Most Favored Nation pricing agreement, which builds on its September 2025 deal with the U.S. government. Under that earlier agreement, Pfizer agreed to make certain U.S. drug prices more comparable with those in other developed countries in exchange for a three-year exemption from certain Section 232 tariffs, subject to additional U.S. manufacturing investment. International operations generated $25.5 billion, or 41% of Pfizer’s 2025 revenue; that revenue rose 2% as total revenue fell 2%.
Pfizer’s 2025 filing says international reference pricing, government procurement systems and price controls can constrain overseas prices. The article says those limits, along with the undisclosed revenue share, make it difficult to estimate how much overseas price gains would reach Pfizer’s earnings and cash flow.
